Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Imatinib Therapy Response”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00858806
What this trial is testing

Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy

Who this might be right for
Chronic Myeloid Leukemia
Università degli Studi di Brescia 78
Testing effectiveness (Phase 2)Ended earlyNCT00320190
What this trial is testing

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Who this might be right for
Leukemia, Myeloid, Chronic
Bristol-Myers Squibb 52
Not applicableStudy completedNCT00896129
What this trial is testing

Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy

Who this might be right for
Chronic Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 448
Not applicableAvailableNCT00854841
What this trial is testing

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Who this might be right for
Chronic Myeloid Leukemia
Pusan National University Hospital
Testing effectiveness (Phase 2)Study completedNCT01774630
What this trial is testing

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)

Who this might be right for
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
University Hospital, Bordeaux 31
Post-approval studies (Phase 4)Ended earlyNCT02086487
What this trial is testing

Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy

Who this might be right for
Myeloid Leukemia, Chronic
King Abdullah International Medical Research Center 98
Large-scale testing (Phase 3)Study completedNCT00264160
What this trial is testing

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Who this might be right for
Leukemia, Myeloid, Chronic
Novartis Pharmaceuticals 36
Testing effectiveness (Phase 2)Study completedNCT02888964
What this trial is testing

Pioglityazone and Imatinib for CML Patients

Who this might be right for
Leukemia, Myeloid, Chronic-Phase
Versailles Hospital 27
Not applicableStudy completedNCT01316250
What this trial is testing

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Who this might be right for
Chronic Myelogenous Leukemia
American University of Beirut Medical Center 13
Testing effectiveness (Phase 2)Study completedNCT00250042
What this trial is testing

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

Who this might be right for
Leukemia, OtherCancer
New Mexico Cancer Research Alliance 6
Post-approval studies (Phase 4)UnknownNCT02602314
What this trial is testing

Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

Who this might be right for
Chronyc Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 450
Large-scale testing (Phase 3)Ended earlyNCT00362466
What this trial is testing

Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Who this might be right for
Leukemia
Bristol-Myers Squibb 3
Testing effectiveness (Phase 2)Study completedNCT02852486
What this trial is testing

Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response

Who this might be right for
Leukemia, Chronic Myeloid
University of Campinas, Brazil 31
Not applicableEnded earlyNCT01073436
What this trial is testing

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Who this might be right for
Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center 7
Post-approval studies (Phase 4)UnknownNCT01901666
What this trial is testing

Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission

Who this might be right for
Chronic Myelogenous LeukemiaShort Stature
Post Graduate Institute of Medical Education and Research, Chandigarh 20
Large-scale testing (Phase 3)Study completedNCT02272777
What this trial is testing

Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Who this might be right for
Leukemia
Novartis Pharmaceuticals 225
Large-scale testing (Phase 3)Ended earlyNCT00519090
What this trial is testing

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Who this might be right for
Myelogenous Leukemia
Novartis Pharmaceuticals 6
Not applicableStudy completedNCT00342056
What this trial is testing

Role of Gene Variation in Effectiveness of Gleevec Treatment

Who this might be right for
CancerBreast Cancer
National Cancer Institute (NCI) 100
Large-scale testing (Phase 3)UnknownNCT04422678
What this trial is testing

The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

Who this might be right for
COVID-19
Alexandria University 30
Testing effectiveness (Phase 2)Looking for participantsNCT05152472
What this trial is testing

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Who this might be right for
Unresectable Gastrointestinal Stromal Tumor (GIST)Locally Advanced Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal Tumor
Centre Leon Berard 110
Next Page